News

arYla is expected to be used to optimise a range of properties critical to the successful development of a therapeutic or diagnostic antibody. The arYla technology results from

BOL-303259-X has been developed for the potential treatment of glaucoma and ocular hypertension and was licensed to Bausch + Lomb by NicOx in March 2010. BOL-303259-X Phase 2b

Pfizer said that the Emphasis-HF trial demonstrated a 37% relative risk reduction for the eplerenone group compared to placebo in the primary composite endpoint of death from CV

Earlier this year, Menicon obtained exclusive distribution rights for Optimed’s products in Japan and Taiwan. Optimed said that CAPTIV8 is a web-based 3D animation software that can be

CytomX CEO Nancy Stagliano said that following closely on the recent Series B financing, they believe these grants are another validation of the potential of their site-directed antibody

The Switzerland-based firm has already applied a different form of Cryptoglyph as a hidden way to mark and protect pharmaceutical and other packaging from counterfeiting. AlpVision claims that

TCA Cellular Therapy said that the funding will help the company to continue the development of adult stem cell therapies for critical limb ischemia, cardiac ischemia, myocardial infarction,

Nutrition 21 has posted a net loss of $898,000 for the first quarter 2010, or $0.01 loss per diluted share, compared to net loss of $643,000, or $0.01

AGP’s generic drug manufacturing facility recently received inspection approvals by both the Food and Drug Board of Ghana (FDB) and the Ghana Standards Board (GSB). EWPI stated that